Clinical trials: Mouth Breathing
- Condition Mouth Breathing
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Asthma
Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma.
- Trial name
- NCT00163527
- Testing
- Roflumilast
- Where
- 24 sites in United States, Austria and 22 more
- Volunteers
- 2,054 people
- Sponsor
- AstraZeneca
PAH
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2)…
- Trial name
- NCT02276872
- Testing
- oral treprostinil
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- United Therapeutics
Asthma, COPD
An Open Study to Assess the Robustness of the CRC749 Inhaler
To confirm the robustness of the CRC749 inhaler.
- Trial name
- NCT02474017
- Testing
- MGR001, CRC749 inhaler
- Where
- 2 sites in United Kingdom
- Volunteers
- 111 people
- Sponsor
- Mylan Pharma UK Ltd.
Asthma
Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets
This study is being conducted to demonstrate the superior clinical effectiveness of Salmeterol/Fluticasone Propionate compared to montelukast in the management of persistent asthma in children aged 6-14 years, and to assess the…
- Trial name
- NCT00328718
- Testing
- montelukast (5mg QD), Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)
- Where
- 26 sites in Argentina, Colombia and 5 more
- Volunteers
- 526 people
- Sponsor
- GlaxoSmithKline
Persistent Fetal Circulation Syndrome
Sildenofil in Persistent Pulmonary Hypertension in Newborns
This study hopes to evaluate the effectiveness of early combined use of Sildenafil and nitric oxide (iNO) in newborns with Persistent pulmonary hypertension (PPHN) and or hypoxemic respiratory failure and assess whether this…
- Trial name
- Sildeno (NCT01558466)
- Testing
- Sildenafil, diluent
- Where
- Qatar
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
Primary Ciliary Dyskinesia
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).
- Trial name
- CLEAN-PCD (NCT02871778)
- Testing
- VX-371, Hypertonic Saline, VX-371 + HS
- Where
- 34 sites in United States, Canada and 6 more
- Volunteers
- 123 people
- Sponsor
- Parion Sciences
Pulmonary Hypertension
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
The purpose of this multi-center international trial is to evaluate the safety and effectiveness of adding iloprost or placebo (an inactive substance that contains no active study drug) to sildenafil therapy for pulmonary…
- Trial name
- VISION (NCT00302211)
- Testing
- Inhaled Iloprost (5 μg), Sildenafil, Bosentan
- Volunteers
- 67 people
- Sponsor
- Actelion
Asthma
Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma
This is a multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study to determine the efficacy and safety of nebulized fluticasone propionate 1mg twice daily compared with oral prednisone…
- Trial name
- NCT01687296
- Testing
- fluticasone propionate inhalation solution, oral prednisone, salbutamol
- Where
- 11 sites in China
- Volunteers
- 261 people
- Sponsor
- GlaxoSmithKline
Lysosomal Storage Disease, Lung Diseases
Biomarker for Maroteaux-Lamy Disease (BioMaroteaux)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Maroteaux-Lamy disease from blood
- Conditions
- Lysosomal Storage Disease, Lung Diseases, Obstructive Sleep Apnoea, Macroglossia
- Trial name
- BioMaroteaux (NCT01458613)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma
The aim of the study is to evaluate efficacy and safety of a 48-week treatment with two doses of tiotropium bromide compared to placebo in adolescent patients with moderate persistent asthma.
- Trial name
- NCT01257230
- Testing
- tiotropium Respimat low dose, tiotropium Respimat high dose
- Where
- 66 sites in United States, Chile and 10 more
- Volunteers
- 398 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Arterial Hypertension
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
- Trial name
- Aspire (NCT01266265)
- Testing
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin
- Where
- 88 sites in United States
- Volunteers
- 1,333 people
- Sponsor
- United Therapeutics
Inflammation, Cough
Evaluation of Efficacy and Safety in Control Cough and the Relief of Nasal Symptoms in Children 2-12 Years Old,Suffering From Cough and Acute Rhinitis
Multicenter clinical trial, phase III, controlled by active medicine, open, randomized, enroll 962 children, 2 to 12 years old, that suffer acute inflammation upper airway characterized by non-productive cough, daytime/nighttime…
- Conditions
- Inflammation, Cough, Rhinitis
- Trial name
- NCT01177852
- Testing
- diphenhydramine + dropropizine + pseudoephedrine, Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Cardiac Diseases, Muscular Weakness
Biomarker for Pompe Disease (BioPompe)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Pompe disease from blood (plasma)
- Conditions
- Cardiac Diseases, Muscular Weakness, Hepato-splenomegaly, Lung Disease
- Trial name
- BioPompe (NCT01457443)
- Where
- 4 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Cough
Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children
Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children
- Trial name
- NCT00520754
- Testing
- levocetirizine dihydrochloride
- Volunteers
- 15 people
- Sponsor
- UCB Pharma
Asthma
A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma
Τherapeutic equivalence, randomized, multiple-dose, placebo-controlled, observer-blind, parallel group design consisting of a 2-week run-in period followed by a 4-week treatment period with Fluticasone propionate 100 mcg/ blister…
- Trial name
- ANASSA-PD (NCT04665895)
- Testing
- Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals, FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK
- Where
- Greece
- Volunteers
- 451 people
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Asthma
A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with…
- Trial name
- FAROS (NCT07525375)
- Testing
- GP MDI, BFF MDI
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 69 people
- Sponsor
- AstraZeneca
Sore Throat, Acute Pharyngitis
Effectiveness and Tolerability of Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)
The aim of this multicentre, actively controlled, randomized, open label, parallel group, prospective, comparator study is to collect data on the clinical effectiveness and tolerability of the medical device ERS09 compared to a…
- Conditions
- Sore Throat, Acute Pharyngitis, Cough
- Trial name
- NCT04203810
- Testing
- Ectoin® Mouth and Throat Spray Althaea Honey (ERS09), EMSER® Hals-und Rachenspray (throat spray)
- Where
- 12 sites in Germany
- Volunteers
- 194 people
- Sponsor
- Bitop AG
Exercise-induced Bronchoconstriction (EIB)
The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)
This study will see if there is a change in breathing after exercising when the child receives study drug ( montelukast or placebo).
- Trial name
- NCT00534976
- Testing
- Comparator: montelukast sodium
- Volunteers
- 364 people
- Sponsor
- Organon and Co
Asthma
Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year
There is a regulatory requirement to evaluate the extent of reduction (if any) of growth velocity associated with inhaled corticosteroid (ICS) containing products that are to be administered to children, and to this end there is…
- Trial name
- NCT02889809
- Testing
- Fluticasone furoate, Montelukast, Short Acting Beta 2 Agonist
- Where
- 54 sites in United States, Argentina and 4 more
- Volunteers
- 477 people
- Sponsor
- GlaxoSmithKline
Asthma, Bronchial
A Study to Evaluate MK0476 and Fluticasone to Control Asthma in Patients With Mild Persistent Asthma (0476-910)
A study to evaluate MK0476 and Fluticasone to control asthma in patients with mild persistent asthma.
- Trial name
- NCT00489346
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 1 Year, Comparator : fluticasone propionate / Duration of Treatment: 1 Year
- Volunteers
- 994 people
- Sponsor
- Organon and Co